Current status and limitations of immunotherapy for breast cancer
Author:
Funder
National Institutes of Health
National Cancer Institute
Roswell Park Cancer Institute
Publisher
Elsevier BV
Subject
Surgery
Reference5 articles.
1. and the IMPassion130 Trial Investigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer;Schmid;N Engl J Med,2018
2. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study;Adams;Ann Oncol,2019
3. and the International Breast Cancer Study Group and the Breast International Group. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial;Loi;Lancet Oncol,2019
4. Cytolytic activity score to assess anticancer immunity in colorectal cancer;Narayanan;Ann Surg Oncol,2018
5. CDK4/6 inhibition triggers anti-tumour immunity;Goel;Nature,2017
Cited by 60 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Biomarker-based immunotherapy in breast cancer;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025
2. Lipid-coated gold nanorods for photoimmunotherapy of primary breast cancer and the prevention of metastasis;Journal of Controlled Release;2024-09
3. Applicability of Quantum Dots in Breast Cancer Diagnostic and Therapeutic Modalities—A State-of-the-Art Review;Nanomaterials;2024-08-31
4. The upregulation of protein disulfide isomerase (PDI) and its potential usage in drug-targeted therapy for breast cancer;Asia Pacific Journal of Molecular Biology and Biotechnology;2024-08-14
5. Infiltration of Common Myeloid Progenitor (CMP) Cells is Associated With Less Aggressive Tumor Biology, Lower Risk of Brain Metastasis, Better Response to Immunotherapy, and Higher Patient Survival in Breast Cancer;Annals of Surgery;2024-06-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3